What To Expect If Republicans Regain Majority: More Executive Actions, Focus On Costs
Lobbyists discuss what will happen with the healthcare agenda if Republicans retake the House in the mid-term elections and the prospects for passing a prescription drug pricing bill before then.
You may also be interested in...
Senate Democrats Running Out Of Time On Drug Pricing Reform
Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.
COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market
Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.
Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform
Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.